Skip to main navigation Skip to search Skip to main content

Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing

  • Cyrus E. Taghavi
  • , Kwang Bok Lee
  • , Wubing He
  • , Gun Keorochana
  • , Samuel S. Murray
  • , Elsa J. Brochmann
  • , Hasan Uludag
  • , Keyvan Behnam
  • , Jeffrey C. Wang
  • David Geffen School of Medicine at UCLA
  • Greater Los Angeles VA Healthcare Center
  • VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California
  • University of Alberta
  • Lanx Inc.

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

Study Design: In vitro and in vivo evaluation of BBP interactions with BMP. Objective: To explore bone morphogenetic protein-binding peptide (BBP)'s mechanism of action, investigate an extended repertoire for BBP applications, and evaluate the usefulness of BBP as a surgical adjuvant when used with recombinant human osteogenic protein-1 (rhOP-1). Summary Of Background Data: Bone morphogenetic proteins (BMPs) are osteoinductive proteins that provide a potential alternative to autograft. Their utility is limited by cost, and potential dose-dependent risks, such as local inflammatory reactions and ectopic bone formation. BBP, a cyclized synthetic peptide, avidly binds recombinant human BMP-2(rhBMP-2) and has been shown to accelerate and enhance its osteogenic qualities. Methods: BBP binding with 4 growth factors from the transforming growth factor-beta family were assessed using surface plasmon resonance. The in vivo retention of rhBMP-2 was quantified by comparing the percentage of retained [I]-labeled rhBMP-2 in absorbable collagen sponge implants with or without BBP at 1, 3, and 7 days postimplantation. The adjunctive effect of BBP with rhOP-1-induced bone growth was evaluated by comparing time to fusion and fusion rates in a rodent posterolateral fusion model with 2 different doses of rhOP-1 with or without BBP. Results: BBP bound all 4 growth factors with an intermediate affinity. The in vivo retention of rhBMP-2 alone ranged from about 40% on day 1 to about 30% on day 7, whereas, the retention of rhBMP-2 in the presence of BBP was about 85% on day 1 and about 55% on day 7. The addition of BBP to rhOP-1 resulted in significantly earlier and greater fusion rates than achieved with rhOP-1 alone. Conclusion: The mechanism of the BBP enhanced osteoinductive properties of BMPs involves the binding and retention of the growth factor, resulting in a prolonged exposure of BMP to the desired fusion site. The use of BBP in conjunction with BMPs may prove to provide satisfactory fusion outcomes, while reducing the costs and side effects associated with BMP use.

Original languageEnglish
Pages (from-to)2049-2056
Number of pages8
JournalSpine
Volume35
Issue number23
DOIs
Publication statusPublished - 1 Nov 2010
Externally publishedYes

Keywords

  • bone graft alternative
  • bone morphogenetic protein
  • bone morphogenetic protein binding peptide
  • osteogenic protein

Fingerprint

Dive into the research topics of 'Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing'. Together they form a unique fingerprint.

Cite this